AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: Access, Cost, and Follow-Up Questions for Memory Clinic Patients

Learn what AAIC 2026 accuracy gains mean for cost, access, and which follow-up questions to ask your clinic.

At AAIC 2026, primary-care accuracy rose from 65% to 93% with PrecivityAD2 results, nearly matching specialists at 94%. The blood test measures amyloid-beta ratios and phosphorylated tau, and the shift affects access, cost, and follow-up for memory-clinic patients. The Alzheimer's Association reports the Swedish real-world study included 1,310 patients with cognitive symptoms and 165 physicians, described in AAIC 2026 primary-care findings. That change lets more patients start workup in primary care instead of waiting for a specialty visit.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What changed for primary-care diagnosis?

The Swedish study followed 1,310 patients with cognitive symptoms and 165 physicians. The Alzheimer's Association reports accuracy rose from 65% to 93% after doctors saw PrecivityAD2 results. Specialists reached 94% in the same study.

PrecivityAD2 measures amyloid-beta ratios and phosphorylated tau. Those are abnormal brain proteins linked to Alzheimer's pathology. The Alzheimer's Association reports doctors changed diagnosis in about one-third of cases and changed care or workup plans for more than half.

Which tests are cleared and for whom?

Being Patient reports four FDA clearances for symptomatic patients only in its timeline of blood-test clearances. Clearances apply only with symptoms, not for screening without symptoms. The Alzheimer's Association July 2025 guideline covers only specialty evaluation of objective impairment. It requires at least 90% sensitivity and 75% specificity for triage use.

Substitution for amyloid PET or spinal-fluid testing requires 90% sensitivity and 90% specificity. Medscape describes a pooled analysis of 2,684 unimpaired adults with very high baseline plasma p-tau217. Risk of cognitive impairment reached about 38% within 5 years and 78% within 10 years. The finding shows future risk, not a current diagnosis.

  • Lumipulse, May 2025
  • Elecsys pTau181, Oct. 2025, for primary-care rule-out
  • PrecivityAD2, Aug. 20, 2026, for ages 40+
  • Elecsys pTau217, Aug. 24, 2026, for rule-in and rule-out

What does testing cost?

HealthcareOnTime lists lab-developed prices at roughly $277 for Labcorp p-tau217 and $399 for Quest AD-Detect in its review of test prices. Panels range up to $626 to $1,450.

FDA-cleared tests have no public price. Medicare has no national coverage policy for screening without symptoms. Ask the clinic for the exact billed test name and written out-of-pocket estimate before blood is drawn.

What should memory-clinic patients ask next?

The Alzheimer's Association notes a positive or borderline result is triage evidence, not a standalone diagnosis, in its blood-biomarker care pathway. Confirmation often needs amyloid PET or lumbar puncture.

Patients should ask whether the test rules out or confirms disease. Ask these three questions at the visit: Bring a list of symptoms, onset dates, and current drugs to the visit. Ask where PET or spinal-fluid confirmation happens locally and how long referral takes.

  • Does this test rule out or confirm Alzheimer's in my case?
  • What follow-up is available locally if the result is positive or borderline?
  • Will the result change workup, referral, or treatment plan?

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.